[Federal Register Volume 78, Number 186 (Wednesday, September 25, 2013)]
[Notices]
[Page 59008]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-23325]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

[Docket No.: PTO-P-2013-0048]


Grant of Interim Extension of the Term of U.S. Patent No. 
5,624,923; Lixivaptan

AGENCY: United States Patent and Trademark Office, Commerce.

ACTION: Notice of Interim Patent Term Extension.

-----------------------------------------------------------------------

SUMMARY: The United States Patent and Trademark Office has issued an 
order granting interim extension under 35 U.S.C. 156(d)(5) for a one-
year interim extension of the term of U.S. Patent No. 5,624,923.

FOR FURTHER INFORMATION CONTACT: Mary C. Till by telephone at (571) 
272-7755; by mail marked to her attention and addressed to the 
Commissioner for Patents, Mail Stop Hatch-Waxman PTE, P.O. Box 1450, 
Alexandria, VA 22313-1450; by fax marked to her attention at (571) 273-
7755; or by email to Mary.Till@uspto.gov.

SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code, 
generally provides that the term of a patent may be extended for a 
period of up to five years if the patent claims a product, or a method 
of making or using a product, that has been subject to certain defined 
regulatory review, and that the patent may be extended for interim 
periods of up to one year if the regulatory review is anticipated to 
extend beyond the expiration date of the patent.
    On July 11, 2013, Cardiokine Biopharma, LLC timely filed an 
application under 35 U.S.C. 156(d)(5) for an interim extension of the 
term of U.S. Patent No. 5,624,923. The patent claims the human drug 
product lixivaptan. The application indicates that a New Drug 
Application, 203,009, for the drug product lixivaptan was filed on 
December 29, 2011, and is currently undergoing regulatory review before 
the Food and Drug Administration for permission to market or use the 
product commercially.
    Review of the application indicates that, except for permission to 
market or use the product commercially, the subject patent would be 
eligible for an extension of the patent term under 35 U.S.C. 156, and 
that the patent should be extended for one year as required by 35 
U.S.C. 156(d)(5)(B). Because the regulatory review period has continued 
beyond the original expiration date of the patent, July 29, 2013, 
interim extension of the patent term under 35 U.S.C. 156(d)(5) is 
appropriate.
    An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S. 
Patent No. 5,624,923 is granted for a period of one year from the 
original expiration date of the patent.

    Dated: September 20, 2013.
Andrew Hirshfeld,
Deputy Commissioner for Patent Examination Policy, United States Patent 
and Trademark Office.
[FR Doc. 2013-23325 Filed 9-24-13; 8:45 am]
BILLING CODE 3510-16-P